Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03404076
Other study ID # GIST m3
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 1, 2014
Est. completion date December 1, 2020

Study information

Verified date April 2022
Source Heidelberg University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study investigates response assessment of gastrointestinal stromal tumors using Dual Energy CT (DECT) in patients undergoing targeted therapy with a TKI Inhibitor.


Description:

Read more »
Read more »

Study Design


Intervention

Diagnostic Test:
Dual Energy CT
Dual Energy CT is performed for diagnostic evaluation in gastrointestinal stromal tumor (GIST) patients undergoing tyrosine kinase inhibitor (TKI) treatment

Locations

Country Name City State
Germany University Center Mannheim Mannheim

Sponsors (4)

Lead Sponsor Collaborator
Heidelberg University Institute of Clinical Radiology and Nuclear Medicine Mannheim, Novartis Pharmaceuticals, Siemens Healthcare Diagnostics Inc

Country where clinical trial is conducted

Germany, 

References & Publications (7)

See more »

Outcome

Type Measure Description Time frame Safety issue
Primary Progression free survival after a three year follow-up To visualize and to evaluate therapy response or stable disease of GIST patients undergoing TKI treatment by Dual Energy CT 3 years follow up
See also
  Status Clinical Trial Phase
Completed NCT02574663 - TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors Phase 1
Active, not recruiting NCT01991379 - MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) Phase 1/Phase 2
Completed NCT01135849 - B-Receptor Signaling in Cardiomyopathy N/A
Completed NCT00623831 - A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen Phase 1
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Completed NCT01294202 - A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST Phase 2
Completed NCT00785785 - A Study of Nilotinib Versus Imatinib in GIST Patients Phase 3
Recruiting NCT02443948 - Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST) N/A
Recruiting NCT01034670 - Advanced Gastrointestinal Endoscopic Imaging N/A
Completed NCT00867113 - Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) Phase 2
Active, not recruiting NCT01391611 - Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) Phase 2
Terminated NCT02452424 - A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Phase 1/Phase 2
Recruiting NCT03594422 - A Study of HQP1351 in Patients With GIST or Other Solid Tumors Phase 1
Recruiting NCT05453292 - Endoscopic Ultrasound Radiofrequency Ablation for GISTs N/A
Completed NCT00780494 - Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma Phase 2
Recruiting NCT04557969 - Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Recruiting NCT04821895 - Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients
Completed NCT01316263 - A Study of IMC-3G3 in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors Phase 2
Terminated NCT00767234 - Permission to Collect Blood Over Time for Research N/A
Recruiting NCT01048281 - Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma